WBJ Exclusive: NIH spinout raises millions to attack drug-resistant cancers with RNA. It has big plans.
A local biotech has secured millions of dollars in new investments to take its RNA therapies for drug-resistant cancers to the clinic.
Gaithersburg’s miRecule Inc. has raised $5.7 million in fresh funding, CEO Anthony Saleh told us Monday, positioning the company to start human testing for its lead candidate to treat head and neck cancer.
Specifically, miRecule is now scaling up and manufacturing drug substance so it can submit an investigational new drug application to the Food and Drug Administration — required to be able to initiate clinical testing. The goal is to start a phase 1 study by 2023, Saleh said.
To get there, Saleh added, miRecule would look to raise a Series A round in the second half of 2022.
Click here to read more via the Washington Business Journal.
Latest posts by BioBuzz Media (see all)
- Emergent BioSolutions Secures Multi-Year Development and Manufacturing Agreement with Providence Therapeutics for its mRNA COVID-19 Vaccine Candidate, PTX-COVID19-B - September 14, 2021
- Ariel Gruswitz, JD, Joins Facility Logix as Associate Director - September 14, 2021
- USP launches an Office of Organizational Culture, Equity and Inclusion Excellence headed by Chief Equity Officer and Senior Advisor Debra Joy Pérez, Ph.D. - September 13, 2021
- Boyds Opens US Office in Philadephia Area - September 13, 2021
- AbbVie and Rockville’s REGENXBIO Announce Eye Care Collaboration - September 13, 2021